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Abstract
Purpose A robust method is required to standardise objective
reporting of diagnostic 123I-mIBG images in neuroblastoma.
Prerequisites for an appropriate system are low inter- and
intra-observer error and reproducibility across a broad disease
spectrum. We present a new reporting method, developed and
tested for SIOPEN by an international expert panel.
Method Patterns of abnormal skeletal 123I-mIBG uptake
were defined and assigned numerical scores [0–6] based
on disease extent within 12 body segments. Uptake inten-
sity was excluded from the analysis. Data sets from 82
patients were scored independently by six experienced spe-
cialists as unblinded pairs (pre- and post-induction chemo-
therapy) and in random order as a blinded study. Response
was defined as ≥50 % reduction in post induction score
compared with baseline.
Results In total, 1968 image sets were reviewed individually.
Response rates of 88 % and 82 % were recorded for patients
with baseline skeletal scores ≤23 and 24-48 respectively, com-
pared with 44 % response in patients with skeletal scores >48
(p = 0.02). Reducing the number of segments or extension
scale had a small but statistically negative impact upon the
number of responses detected. Intraclass correlation coeffi-
cients [ICCs] calculated for the unblinded and blinded study
were 0.95 at diagnosis and 0.98 and 0.99 post-induction che-
motherapy, respectively.
Conclusions The SIOPEN mIBG score method is reproduc-
ible across the full spectrum of disease in high risk neuroblas-
toma. Numerical assessment of skeletal disease extent avoids
subjective evaluation of uptake intensity. This robust approach
provides a reliable means with which to examine the role of
123I mIBG scintigraphy as a prognostic indicator in
neuroblastoma.
Keywords Neuroblastoma . 123-meta-iodobenzylguanidine
[123I-mIBG] . Imaging . Scintigraphy . Skeleton .
SIOPEN-R-NET
Introduction
Whole-body imaging us ing radio labe l led meta-
iodobenzylguanidine [mIBG] has an established place in stag-
ing and monitoring treatment response in neuroblastoma [NB]
[1, 2]. In addition to descriptive image reporting, a
* V. Lewington
Valerie.lewington@kcl.ac.uk
1 King’s College, London, UK
2 Radiology and Nuclear Medicine, Ghent University, Ghent, Belgium
3 Department for Studies and Statistics on Integrated Research and
Projects (S2IRP), Children’s Cancer Research Institute,
Vienna, Austria
4 Schneider Children’s Medical Centre of Israel, Petach-Tikva, Israel
5 CHLS, Pierre-Benite, France
6 Cross Cancer Institute, Edmonton, Canada
7 Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei
Tumori, Milan, Italy
8 Northern Ireland Cancer Centre, Belfast, UK
9 St Jude’s Children’s Research Hospital, Memphis, USA
10 AITAustrian Institute of Technology GmbH Safety & Security
Department, Information Management & eHealth, Vienna, Austria
11 AKH, Vienna, Austria
12 St. Anna Children’s Hospital and Medical University,
Vienna, Austria
Eur J Nucl Med Mol Imaging
DOI 10.1007/s00259-016-3516-0
standardised, objective evaluation method is required to com-
pare patient populations and treatment responses in multi-
centre clinical trials. Pre-requisites for a suitable scoring sys-
tem are i. reproducibility, ii. validity across the full spectrum
of disease, and iii. straightforward application by trained spe-
cialists with minimal requirement for additional training.
Several semi-quantitative mIBG reporting methods have
been described previously, based upon the allocation of nu-
merical scores to document mIBG positive disease extent and
intensity of mIBG uptake compared with reference normal
tissues [3–6]. In contrast to positron emission tomography
[PET] imaging, where standardised uptake value (SUV) mea-
surements are well established [7, 8] visual assessment of
mIBG uptake intensity is subjective and highly variable.
Variability could be reduced by focusing on disease extent
rather than uptake intensity in individual lesions. A new,
semi-quantitative objective reporting method based on this
principle has been developed and tested by an international
panel of seven experienced nuclear medicine specialists.
Method
The skeletal distribution of mIBG was recorded in 12 anatom-
ical body segments (Table 1) as follows: skull, thoracic cage,
proximal right upper limb, distal right upper limb, proximal
left upper limb, distal left upper limb, spine, pelvis, proximal
right lower limb, distal right lower limb, proximal left lower
limb, and distal left lower limb. The extent and pattern of
skeletal mIBG involvement were scored using a 0–6 scale to
discriminate between focal discrete lesions and patterns of
more diffuse infiltration as described in Table 2. Examples
of the different extension scores are given in Figs. 1 and 2.
Primary tumours and soft tissue disease were evaluated
separately, focusing on lesion size relative to normal
myocardium.
This method was applied to anonymised mIBG image sets
performed in children with NB uniformly treated within the
SIOPEN-R-NET High Risk NB Study. Parental written in-
formed consent was obtained at trial entry. All imaging pro-
cedures were undertaken using iodine I-123 (123I) radio-
labelled mIBG in accordance with local hospital acquisition
protocols based upon published European guidelines [9].
Imaging was performed at diagnosis and on completion of
rapid COJEC induction chemotherapy [10]. Image data from
participating European centres were stored electronically on
the SIOPEN-R-NET database.
For the purpose of the review, the minimum image quality
standard was defined as whole-body anterior and posterior
scans or overlapping anterior and posterior static images in-
cluding all peripheries, acquired within 18-24 h of intravenous
tracer 123I-mIBG injection. JPEG, TIFF, and DICOM image
formats were included. As few centres undertake paediatric
single photon emission tomography (SPECT) routinely,
SPECT data were omitted from the analysis. No fused
SPECT/CT data were reviewed. All mIBG images held on
the SIOPEN-R-NET database were considered. Eighty-two
patients met the review criteria of two complete, high quality
data sets obtained at diagnosis and on completion of rapid
COJEC induction chemotherapy. The number of individual
images contained within each data set varied, depending on
whether whole body or overlapping static views were
acquired.
Images were scored independently by six nuclear med-
icine specialist panel members as pre- and post-treatment
image pairs (Bunblinded^) and again as individual scans
in random order as a blinded study. Three hundred and
twenty-eight separate data sets were reviewed by each
panel member, and 1968 complete reviews were per-
formed. File headers indicated the primary tumour site,
but no further clinical information or correlative imaging
was made available.
The 12-segment method used does not map exactly to
mIBG scoring systems reported previously [3–6]. To assess
whether the method could be simplified by reducing the num-
ber of surveyed segments, results were compared with a hy-
pothetical seven-segment model derived from earlier pub-
lished methods [3–6]. (Table 1). The 0–6 scale demonstrating
skeletal disease extent was compared with a 0–3 scale de-
scribed previously (Table 2) [3, 5].
Changes in primary and soft tissue tumour size and uptake
pattern were assessed qualitatively from post-treatment im-
ages in the unblinded study.
Interclass correlation coefficients were used to assess intra-
and inter-observer variability. The frequency of skeletal me-
tastasis by anatomical site and relative contribution of differ-
ent anatomical regions to overall score were calculated.
The typical time to score a downloaded, complete image
set was noted.
Table 1 12 segment
SIOPEN skeletal score
versus a comparator 7
segment score
12 segment method 7 segment method
Skull Skull
Right humerus Upper limbs
Left humerus
Right radius/ulna
Left radius/ulna
Thoracic cage Thoracic cage
Spine Spine
Pelvis Pelvis
Right femur Femora
Left femur
Right tibia/fibula Distal lower limbs
Left tibia/fibula
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Statistical method
Skeletal mIBG scores were compared at diagnosis and after
rapid COJEC induction chemotherapy using Spearman corre-
lation coefficients. Spearman Rank order correlation is a non-
parametric measure of association based on the ranks of data
values between−1 and 1. A positive relationship exists if the
correlation is greater than 0. Bland Altman plots [11] were
used to evaluate agreement between the new score method
and alternative systems, comparing 0–6 vs. 0–3 score scales
and 12 vs. 7 body segment scores respectively. The Bland–
Altman plot displays the difference between methods against
their mean.
Themaximal score of 72was divided in thirds to categorize
patients at diagnosis in low (score 0–23), intermediate (24–
48), and high (49–72) skeletal scores. Response to induction
chemotherapy (defined as ≥50 % score decrease) was com-
pared for each group using the chi squared test.
Intraclass correlation coefficients (ICC) were used to assess
the reliability between multiple observers [12]. ICC is defined
as the ratio of the between-patient variance to the total vari-
ance, which is a combination of inter-patient and intra- patient
variance (i.e. variance between observers) and estimated using
a random effect model.
Results
1968 mIBG data sets from 34 participating SIOPEN-R-NET
centres in 12 European countries were reviewed. An equal
number of images was reviewed in DICOM format and as
JPEG/TIFF screen capture images. Images from 79 % of pa-
tients were acquired as static, overlapping, single field of view
studies, 15 % as whole-body only scans, and 6 % as whole-
body scans with additional static single field of view images.
Additional tomographic images were available in four pa-
tients, but were excluded from the analysis. Scores for the
skeleton, primary tumour and soft tissues and were analysed
separately.
Assessment of skeletal tumour burden
The most common sites of skeletal metastatic involvement at
baseline were femora (67 % of patients), spine (66 %), pelvis
(65 %), skull (63 %), and thoracic cage (60 %), followed by
the humeri (53 %) and distal lower limbs (48 %). Distal upper
limb metastasis occurred less frequently (14 %).
Correlation of initial and post-treatment skeletal score
A significant correlation was shown between the initial skel-
etal score at diagnosis and post-treatment score. Patients with
extensive skeletal metastases at diagnosis had, on average,
higher post induction chemotherapy scores (Spearman corre-
lation coefficient + 0.478, < 0.001) (Fig. 3).
Patients were assigned to one of three groups according to
skeletal score at diagnosis: low score (≤23) n = 45 (55 %);
intermediate score (23 – 48) n = 28 (34 %); high score (>48)
n = 9 (11 %). Skeletal response, defined as a 50 % or greater
score reduction following rapid COJEC induction chemother-
apy, was analysed using the Chi-squared test. Twenty patients
had no skeletal mIBG uptake at diagnosis, precluding quanti-
tative response assessment using this method. Forty-nine of 62
patients who had mIBG positive skeletal metastases at diag-
nosis had a 50 % or greater reduction in skeletal mIBG score
following induction chemotherapy. Patients with a baseline
score of >48 achieved a statistically significant poorer skeletal
response rate to induction therapy (n = 62, p < 0.02). These
results are summarised in Table 3.
Table 2 SIOPEN skeletal score
0–6 extension scale versus
comparator 0-3 scale
123 I-mIBG skeletal extension scale 0–6 Extension scale 0–3
Skeletal
score
Descriptor Score Descriptor
0 No abnormality 0 No abnormality
1 1 discrete focus 1 Solitary abnormality
2 2 discrete foci 2 >1 abnormality
3 3 discrete foci
4 >3 discrete foci or diffuse involvement < 50 %
bone
3 Diffuse (>50 % of segment
involved)
5 Diffuse involvement >50–95 % whole bone
6 Uniform, diffuse whole bone involvement
Fig. 1 Normal anterior 123I-mIBG images showing physiological
salivary, myocardial, and hepatic uptake and excreted activity in the
urinary bladder. Skeletal Score = 0
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Skeletal disease extent scores and segment number
justification
SIOPEN skeletal disease extent scores were added together to
approximate a published method [3] based on a 0–3 scale as
shown in Table 2.
The two scoring methods are compared as Bland–Altman
plots in Fig. 4a. In patients with mIBG positive skeletal dis-
ease at diagnosis, a significantly higher number of favourable
responses (i.e. > 50 % skeletal score reduction) was recorded
using the 0–6 scale compared with the 0–3 scale (p < 0.001),
although the mean difference between methods was small
(0.03+/- 0.26).
To assess whether the method could be simplified by re-
ducing the number of skeletal segments, skeletal disease ex-
tent scores were re-calculated based on 7 body segments as
summarised in Table 1. Methods were compared using Bland
and Altman plots as shown in Fig. 4b. In patients with mIBG
positive skeletal disease at diagnosis, higher response rates
after rapid COJEC induction chemotherapy were recorded
Fig. 3 Pre-treatment skeletal
mIBG score vs. post-induction
chemotherapy score correlation:
Spearman correlation coefficient
+0.48, <0.001
Fig. 2 123I-mIBG images
illustrating abnormal skeletal
uptake corresponding to scores 1–
6. Top row: individual lesions are
arrowed. Bottom row: patterns of
diffuse skeletal uptake
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Fig. 4 a. Comparison between
0–3 and 0–6 skeletal extension
scales: Bland–Altman Plot: mean
−0.014; standard deviation 0.19,
95 %CI -0.06-0.33 b.
Comparison between seven and
12 skeletal segment scales:
Bland–Altman Plot: mean -0.06;
standard deviation 0.06, 95 %CI -
0.02-0.009
Table 3 Skeletal response
frequencies versus pre-treatment
skeletal mIBG score
Baseline Skeletal score <50 % post treatment score
reduction
≥50 % post treatment score
reduction
Total
n % n % n
<23 3 12 % 22 88 % 25
23–48 5 18 % 23 82 % 28
>48 5 56 % 4 44 % 9
Total 13 21 % 49 79 % 62
Chi Square 7.87: p-value 0.020
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using the 12 segment method compared with a seven-segment
technique (p = 0.014) although the mean difference between
methods was low (0.01+/-0.08).
Inter-observer and intra-observer reproducibility
and time to score
Skeletal disease extent scores were analysed to assess inter-
and intra-observer reproducibility. Intraclass correlation coef-
ficients (ICC) calculated for the unblinded study were 0.95 at
diagnosis and 0.98 on completion of induction chemotherapy.
Corresponding ICCs for the blinded study were 0.95 and 0.99,
respectively.
The time to analyse and score an individual skeletal data set
after data upload was typically 2 minutes, depending on scan
complexity. The short time for analysis was facilitated by
assessing images in a logical cranio-caudal anatomical se-
quence, separating right and left limb scores and by avoiding
assessment of uptake intensity.
Assessment of soft tissue involvement
Abnormal 123I-mIBG soft tissue uptake, excluding the
primary tumour, was difficult to separate from skeletal
and physiological activity on pre- and post-treatment pla-
nar images. Soft tissue disease was discernible in 11 pa-
tients at diagnosis and in 8 on completion of induction
chemotherapy. The small sample size precluded further
ICC correlation.
Primary tumour assessment
The SIOPEN-R-NET database documented 72 abdominal,
five thoracic, and five thoraco-abdominal primary tumours
in the reviewed patient group. Excluding four patients who
underwent primary tumour resection prior to mIBG imaging,
the primary tumour was correctly identified by 123I-mIBG
imaging in 73/78 patients at diagnosis.
Primary tumour response was recorded as qualitative size
reduction by at least 50 % between pre- and post-induction
chemotherapy scans. Data from 62 patients with mIBG posi-
tive primary tumours and skeletal metastases were analysed.
In this cohort 22 patients (35 %) had a response of the primary
tumour post induction chemotherapy. Twenty-one out of 62
responded in both the primary tumour and skeleton. One child
had a 50 % primary tumour response but less than 50 % skel-
etal response. A significant correlation was shown between
primary tumour and skeletal metastatic response as assessed
by mIBG imaging (Spearman correlation coefficient +0.47,
<0.001).
Discussion
The clinical significance of standardised, objective mIBG
reporting in neuroblastoma is well recognised. Earlier
reporting methods for mIBG scintigraphy [13] included
semi-quantitative evaluation of the intensity of mIBG uptake
compared with reference normal tissue. This is feasible when
images are acquired as whole-body scans in which the refer-
ence tissue (liver) is included in the data set. Uptake intensity
cannot, however, be determined from single-view, static im-
ages where the reference tissue is excluded from the field of
view. Although older children may be able to co-operate with
lengthy whole-body scans, the majority of SIOPEN-R-NET
participating trial centres prefer to acquire overlapping static
images in young patients. In accordancewith published guide-
lines [9], images are acquired either for a minimum of 600 sec-
onds or until a pre-determined total number of counts per
image has been achieved, whichever occurs earlier.
Recommended total counts per image vary according to body
area.
Thus, the relative intensity of 123I-mIBG uptake between
body areas cannot be assessed from single field of view images
unless every image has been acquired for an identical period of
time. The strict imposition of this requirement is unworkable in
paediatric oncology practice. For these reasons, we conclude
that subjective intensity measurements should be excluded
from semi-quantitative 123I-mIBG scoring methods. The new
score method was developed specifically to avoid this pitfall.
Lesion intensity values have accounted for up to 60 % of
total score in semi-quantitative mIBG evaluation methods pub-
lished previously [3, 4]. Exclusion of intensity results would,
however, lead to a very restricted score range, which might limit
the sensitivity of semi-quantitative approaches for response as-
sessment. We have overcome this both by expanding the scale
used to describe tumour extent to 0–6 and by increasing the
number of individual body segments evaluated to 12, generating
a score range of 0–72. In the review population, this detailed
evaluation allowed clear discrimination between induction che-
motherapy responders and non-responders.
Data reviewed were acquired from 34 centres in 12
European countries and are considered representative of an
unselected paediatric NB population. The high inter- and
intra-observer ICCs achieved confirm the reproducibility of
the proposed score method and that this approach is valid
across a broad spectrum of high-risk NB disease. The scoring
method was applied consistently by all members of the review
panel who worked independently using electronically stored
anonymised data. The method is, therefore, straightforward
and can be applied by trained nuclear medicine specialists
withminimal additional briefing. Further, the focus on skeletal
extension score rather than uptake intensity reduced the time
required for data review, the typical time to evaluate a single
uploaded study being in the order of 2 minutes. Image scoring
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in a logical cranio-caudal anatomical sequence proved
straightforward in practice and speed of reporting was im-
proved by evaluating right and left limb scores separately.
The method was applied intuitively by nuclear medicine
specialists and facilitated peer review of large numbers of
scans within a manageable time frame. As no time penalty
has been encountered in undertaking the detailed segmen-
tal assessment, we suggest that this method is sufficiently
promising and time-efficient to be adopted in routine
practice.
In common with published experience, the extent of
skeletal involvement at diagnosis correlates well with re-
sponse to rapid COJEC induction chemotherapy, as
assessed by post-treatment 123I-mIBG scans [3–5]. In
our study group, children with higher skeletal scores
(>48) at diagnosis had a lower chance of obtaining a
50 % reduction compared to the low (0–23) and interme-
diate score (24–48) groups. Establishing a score threshold
that could predict both treatment response at diagnosis
and outcome would allow early identification of patients
suitable for dose intensification. This is a key area for
future research and further studies are in progress.
Although a strong correlation was shown between
response to induction chemotherapy in the primary tu-
mour site and skeletal metastases, only 35 % of children
within the review group achieved a 50 % or greater
metabolic response at the primary tumour site, com-
pared with 79 % who achieved at least 50 % reduction
in skeletal mIBG score. The demonstration of differen-
tial response between metastatic and primary tumour
sites in this study is consistent with clinical experience
and confirms the importance of additional intervention
for local disease control in high risk neuroblastoma.
Although planar imaging is probably adequate to assess
skeletal response, it is likely that the sensitivity of 123I-
mIBG in evaluating primary tumours would be im-
proved by SPECT/CT imaging. The unexpectedly low
primary tumour metabolic response rate observed may,
therefore, be partly attributable to a lack of tomographic
information in the reviewed data set. Gamma cameras
with SPECT/CT capability are becoming more widely
available in Europe but longer image acquisition times
and radiation dose concerns resulting from the CT com-
ponent still present logistic difficulties in the paediatric
population. In most centres, 123I-mIBG SPECT/CT is
not routinely performed in young children unless uptake
in overlapping tissues precludes accurate tumour defini-
tion, where this discrimination would be likely to alter
management.
Evidence supporting the role of PET-tracers such as
fluorine-18 deoxyglucose (FDG) and gallium-68 somatostatin
analogues (DOTANOC, DOTATOC, DOTATATE) in
assessing NB is emerging [13, 14] and merits further
comparison with 123I-mIBG SPECT/CT. A validated score
method for tomographic mIBG scans will be required for this
purpose.
Excluding the primary tumour, soft tissue disease was un-
usual at diagnosis in the study population. The separate eval-
uation of abnormal 123I-mIBG soft tissue uptake, other than
the primary tumour, proved very difficult on pre- and post-
treatment planar images, particularly in central thoracic and
abdominal compartments where osseous and soft tissue tu-
mour uptake was often superimposed. This may be more
problematic in children with relapsed NB, in whom soft tissue
disease occurs more frequently. While planar scintigraphy is
sufficient to document skeletal lesions, soft tissue disease is
better evaluated and differentiated from physiological uptake
by tomographic imaging. We, therefore, share the pragmatic
view of other groups [4] that all disease should be scored
within anatomical segments without differentiating between
skeletal and soft tissue lesions. Given the minor contribution
of soft tissue disease relative to skeletal tumour burden in the
study population, this approach would have had no significant
impact upon the results reported.
Although all reviewed data sets fulfilled minimum stan-
dards for completeness and specified format, a wide variation
in image quality was observed. In general, image quality im-
proved between data acquired in the early and later stages of
the SIOPEN-R-NET trial. This reflects improvements both in
gamma camera performance and European paediatric nuclear
medicine practice that have occurred within the time frame of
the high risk NB trial. Specific observations regarding mIBG
imaging procedures will be reported separately.
Data sets included for review were stored electronically
on the SIOPEN-R-NET database in a variety of formats.
Images held in DICOM format facilitated data manipula-
tion, contrast, and window thresholding. This increased
the speed and sensitivity of image review compared with
snapshot scans captured as JPEG, Bitmap, or TIFF files.
We recommend that storage of image data in DICOM or
Interfile format be adopted as the standard for clinical
trials.
At present, 123I-mIBG imaging is the only widely available,
objective measure of metabolic treatment response in NB. The
semi-quantitative scoring method developed and described
here is straightforward, scientifically robust and will enhance
the reproducibility of 123I-mIBG image reporting in both clin-
ical practice and clinical trials. The method would also provide
a basis for comparing mIBG imaging with FDG PET CT and
radiolabelled somatostatin analogues in NB.
The proposed score method draws on extensive pub-
lished previous experience, but the avoidance of subjec-
tive uptake intensity assessment and detailed focus on
skeletal tumour extent as a prognostic factor are new.
The method has been validated in a multi-centre, interna-
tional patient population and will be tested prospectively
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within the SIOPEN-R-NET high risk NB trial. We con-
clude that this approach represents a positive step in NB
management, sets a new standard for response assessment
and could be applied to determine the role of 123I-mIBG
scintigraphy as an independent prognostic indicator in
NB.
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